Another study showed that GLP-1 RA liraglutide and exenatide can improve left ventricular ejection fraction (LVEF) in patients with heart failure, due to their anti-inflammatory, anti-fibrotic and anti-oxidant effects leading to an improvement of endothelial functions and glucose uptake by myocardial cells [56]; these effects may enhance systolic function, particularly in patients with comorbid heart failure and diabetes. The gene discussed is GCG; the disease is diabetes mellitus.